LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HG-5-88-01 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 2681 | 3643 | 0.7361 | 0.5798 |
| SK-BR-3 | HG-5-88-01 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 2967 | 3643 | 0.8148 | 0.7086 |
| SK-BR-3 | HG-5-88-01 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 2878 | 3643 | 0.7913 | 0.6716 |
| SK-BR-3 | HG-5-88-01 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 2858 | 3643 | 0.7865 | 0.6649 |
| SK-BR-3 | HG-5-88-01 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 2638 | 3643 | 0.7251 | 0.5626 |
| SK-BR-3 | HG-5-88-01 | 10 | uM | LJP6 | 72 | hr | 1476 | 1696 | 3643 | 0.4669 | 0.1134 |
| SK-BR-3 | HG-6-64-01 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 4118 | 3643 | 1.1322 | 1.2035 |
| SK-BR-3 | HG-6-64-01 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 3681 | 3643 | 1.0118 | 1.0198 |
| SK-BR-3 | HG-6-64-01 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3252 | 3643 | 0.8934 | 0.8348 |
| SK-BR-3 | HG-6-64-01 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 2797 | 3643 | 0.7691 | 0.6359 |
| SK-BR-3 | HG-6-64-01 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 2021 | 3643 | 0.5571 | 0.2763 |
| SK-BR-3 | HG-6-64-01 | 10 | uM | LJP6 | 72 | hr | 1476 | 809 | 3643 | 0.2232 | -0.3703 |
| SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 1348 | 3772 | 0.3575 | -0.0656 |
| SK-BR-3 | Neratinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 1374 | 3772 | 0.3644 | -0.0516 |
| SK-BR-3 | Neratinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1340 | 3772 | 0.3554 | -0.0694 |
| SK-BR-3 | Neratinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 1446 | 3772 | 0.3834 | -0.0155 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1349 | 3772 | 0.3577 | -0.0650 |
| SK-BR-3 | Neratinib | 10 | uM | LJP5 | 72 | hr | 1476 | 1080 | 3772 | 0.2865 | -0.2065 |
| SK-BR-3 | JW-7-24-1 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 2791 | 3643 | 0.7664 | 0.6299 |
| SK-BR-3 | JW-7-24-1 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 2887 | 3643 | 0.7922 | 0.6711 |
| SK-BR-3 | JW-7-24-1 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 2648 | 3643 | 0.7297 | 0.5722 |
| SK-BR-3 | JW-7-24-1 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 2476 | 3643 | 0.6784 | 0.4806 |
| SK-BR-3 | JW-7-24-1 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 2056 | 3643 | 0.5647 | 0.2881 |
| SK-BR-3 | JW-7-24-1 | 10 | uM | LJP6 | 72 | hr | 1476 | 1074 | 3643 | 0.2972 | -0.2170 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3730 | 3772 | 0.9890 | 0.9838 |